A Phase 2 interventional study of Enclitide Chloride and Placebo in Hypercholesterolemia and Familial Hypercholesterolemia, sponsored by Merck Sharp & Dohme LLC. Completed at 63 sites in 8 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-12-09.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies in Hypercholesterolemia by Merck & Co., Inc — 1 open to participants now, 3 under way, 3 of them phase 3. Hypercholesterolemia · Merck & Co., Inc.
Among the 29 studies in Hypercholesterolemia by Merck & Co., Inc, this one is the 17th largest by enrollment of the 27 interventional ones that give a count, is one of 3 that started in 2022, is one of 4 in phase 2, and was the 20th registered.
1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.
Browse Hypercholesterolemia studies →1 of the 29 studies in Hypercholesterolemia by Merck & Co., Inc is open now, in 1 country. Recruiting first, the newest first:
Merck Sharp & Dohme LLC · Sites in India
Ages 18+
By country, each count listing its studies:
Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 3 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 381 is above the median of 110 across 976 interventional studies indexed under Hypercholesterolemia.
Median enrollment 500 across the 27 interventional studies, 901 across the 2 observational. Of the 26 that completed or were terminated, 16 (62%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
1 of the studies in Hypercholesterolemia by Merck & Co., Inc that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07821944Phase 3Merck Sharp & Dohme LLCA Clinical Study of Enlicitide (MK-0616) in Adults With Hyperlipidemia in India (MK-0616-038) | 2027-11-26 |
Add it to your calendar (.ics) → With an account.
Among the 29 studies in Hypercholesterolemia by Merck & Co., Inc, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and safety of enclitide chloride, an oral PCSK9 inhibitor, in lowering low-density lipoprotein cholesterol (LDL-C) in participants with hypercholesterolemia. The primary hypothesis is that at least one of the four doses of enclitide chloride tested in this study is superior to placebo on percent change from baseline in LDL-C at Week 8.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive 6 mg of enlicitide chloride orally QD for 8 weeks
Drug: Enclitide Chloride
Participants will receive 12 mg of enlicitide chloride orally QD for 8 weeks
Drug: Enclitide Chloride
Participants will receive 18 mg of enlicitide chloride orally QD for 8 weeks
Drug: Enclitide Chloride
Participants will receive 30 mg of enlicitide chloride orally QD for 8 weeks
Drug: Enclitide Chloride
Participants will receive enlicitide chloride-matching placebo orally QD for 8 weeks
Drug: Placebo
Enclitide Chloride administered orally
Also known as: MK-0616
Placebo matching enclitide chloride administered orally
Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Week 8
Blood samples were collected at baseline and after 8 weeks of treatment to assess mean percent change in LDL-C. Based on a constrained longitudinal analysis (cLDA) model including terms for treatment, time, baseline statin intensity, baseline renal function, and the interaction of treatment by time. The percent change from baseline in LDL-C at week 8 was reported.
Time frame: Baseline and up to Week 8
Percentage of Participants Who Experienced One or More Adverse Events (AEs)
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The percentage of participants who experienced at least one AE was reported.
Time frame: Up to approximately 17 Weeks
Percentage of Participants Who Discontinued Study Intervention Due to AEs
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The percentage of participants who discontinued study intervention due to AEs was reported.
Time frame: Up to approximately 9 Weeks
Percent Change From Baseline in Apolipoprotein B (ApoB) at Week 8
Blood samples were collected at baseline and after 8 weeks of treatment to assess mean percent change in ApoB. The least square mean and 95% CI were obtained from fitting a cLDA model including terms for treatment, time, baseline statin intensity, baseline renal function, and the interaction of treatment by time. The percent change from baseline in ApoB at week 8 was reported.
Time frame: Baseline and up to Week 8
Percent Change From Baseline in Non-High-density Lipoprotein Cholesterol (Non-HDL-C) at Week 8
Blood samples were collected at baseline and after 8 weeks of treatment to assess mean percent change in non-HDL-C. The least square mean and 95% CI were obtained from fitting a cLDA model including terms for treatment, time, baseline statin intensity, baseline renal function, and the interaction of treatment by time. The percent change from baseline in non-HDL-C at week 8 was reported.
Time frame: Baseline and up to Week 8
Percentage of Participants With LDL-C Value at Goal at Week 8
LDL-C goal was defined as: LDL-C \<70 mg/dL (\<1.81 mmol/L) in participants with clinical atherosclerotic cardiovascular disease (ASCVD), LDL-C \<100 mg/dL (\<2.59 mmol/L) in participants with an ASCVD risk-equivalent and/or a 10-year risk of having an ASCVD event that is ≥7.5%, OR LDL-C \<130 mg/dL (\<3.37mmol/L) in participants with a 10-year risk of having an ASCVD event that is ≥5.0% and \<7.5%. The percentage of participants with LDL-C value at goal at week 8 were reported.
Time frame: Week 8
Of 668 participants screened for inclusion, 381 were randomized 1:1:1:1:1 to receive MK-0616 6 mg, 12 mg, 18 mg, 30 mg, or placebo. Of the 381 randomized participants, one participant did not receive at least one dose of study intervention.
| Milestone | MK-0616 6 mg | MK-0616 12 mg | MK-0616 18 mg | MK-0616 30 mg | Placebo |
|---|---|---|---|---|---|
| Started | 77 | 76 | 76 | 76 | 76 |
| Treated | 77 | 76 | 76 | 76 | 75 |
| Completed | 75 | 76 | 74 | 74 | 74 |
| Not completed | 2 | 0 | 2 | 2 | 2 |
| Withdrew: Death | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Physician decision | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Screen failure | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 1 | 0 | 1 | 1 | 0 |
| Withdrew: Not recorded | 0 | 0 | 0 | 1 | 0 |
Blood samples were collected at baseline and after 8 weeks of treatment to assess mean percent change in LDL-C. Based on a constrained longitudinal analysis (cLDA) model including terms for treatment, time, baseline statin intensity, baseline renal function, and the interaction of treatment by time. The percent change from baseline in LDL-C at week 8 was reported.
| Percentage Change | MK-0616 6 mg | MK-0616 12 mg | MK-0616 18 mg | MK-0616 30 mg | Placebo |
|---|---|---|---|---|---|
| Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Week 8 | -40.0 (-45.2 to -34.8) | -54.5 (-59.8 to -49.2) | -57.9 (-63.2 to -52.6) | -59.7 (-65.0 to -54.5) | 1.2 (-4.1 to 6.5) |
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The percentage of participants who experienced at least one AE was reported.
| Percentage of Participants | MK-0616 6 mg | MK-0616 12 mg | MK-0616 18 mg | MK-0616 30 mg | Placebo |
|---|---|---|---|---|---|
| Percentage of Participants Who Experienced One or More Adverse Events (AEs) | 44.2 | 39.5 | 43.4 | 42.1 | 44.0 |
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The percentage of participants who discontinued study intervention due to AEs was reported.
| Percentage of Participants | MK-0616 6 mg | MK-0616 12 mg | MK-0616 18 mg | MK-0616 30 mg | Placebo |
|---|---|---|---|---|---|
| Percentage of Participants Who Discontinued Study Intervention Due to AEs | 2.6 | 0.0 | 2.6 | 2.6 | 1.3 |
Blood samples were collected at baseline and after 8 weeks of treatment to assess mean percent change in ApoB. The least square mean and 95% CI were obtained from fitting a cLDA model including terms for treatment, time, baseline statin intensity, baseline renal function, and the interaction of treatment by time. The percent change from baseline in ApoB at week 8 was reported.
| Percentage Change | MK-0616 6 mg | MK-0616 12 mg | MK-0616 18 mg | MK-0616 30 mg | Placebo |
|---|---|---|---|---|---|
| Percent Change From Baseline in Apolipoprotein B (ApoB) at Week 8 | -32.8 (-37.6 to -27.9) | -45.8 (-50.7 to -40.9) | -48.7 (-53.6 to -43.8) | -51.8 (-56.7 to -47.0) | 0.0 (-4.9 to 4.9) |
Blood samples were collected at baseline and after 8 weeks of treatment to assess mean percent change in non-HDL-C. The least square mean and 95% CI were obtained from fitting a cLDA model including terms for treatment, time, baseline statin intensity, baseline renal function, and the interaction of treatment by time. The percent change from baseline in non-HDL-C at week 8 was reported.
| Percentage Change | MK-0616 6 mg | MK-0616 12 mg | MK-0616 18 mg | MK-0616 30 mg | Placebo |
|---|---|---|---|---|---|
| Percent Change From Baseline in Non-High-density Lipoprotein Cholesterol (Non-HDL-C) at Week 8 | -34.4 (-39.6 to -29.2) | -49.0 (-54.3 to -43.7) | -51.8 (-57.1 to -46.4) | -54.3 (-59.6 to -49.1) | 1.5 (-3.9 to 6.8) |
LDL-C goal was defined as: LDL-C \<70 mg/dL (\<1.81 mmol/L) in participants with clinical atherosclerotic cardiovascular disease (ASCVD), LDL-C \<100 mg/dL (\<2.59 mmol/L) in participants with an ASCVD risk-equivalent and/or a 10-year risk of having an ASCVD event that is ≥7.5%, OR LDL-C \<130 mg/dL (\<3.37mmol/L) in participants with a 10-year risk of having an ASCVD event that is ≥5.0% and \<7.5%. The percentage of participants with LDL-C value at goal at week 8 were reported.
| Percentage of Participants | MK-0616 6 mg | MK-0616 12 mg | MK-0616 18 mg | MK-0616 30 mg | Placebo |
|---|---|---|---|---|---|
| Percentage of Participants With LDL-C Value at Goal at Week 8 | 80.5 | 85.5 | 90.8 | 90.8 | 9.3 |
Collected over Up to approximately 17 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| MK-0616 6 mg | 0/77 (0%) | 1/77 (1.3%) | 11/77 (14.3%) |
| MK-0616 12 mg | 0/76 (0%) | 3/76 (3.9%) | 13/76 (17.1%) |
| MK-0616 18 mg | 1/76 (1.3%) | 2/76 (2.6%) | 15/76 (19.7%) |
| MK-0616 30 mg | 0/76 (0%) | 2/76 (2.6%) | 8/76 (10.5%) |
| Placebo | 0/76 (0%) | 0/75 (0%) | 15/75 (20%) |
| Event | MK-0616 6 mg | MK-0616 12 mg | MK-0616 18 mg | MK-0616 30 mg | Placebo |
|---|---|---|---|---|---|
| Acute left ventricular failureCardiac disorders | 0/77 | 0/76 | 1/76 | 0/76 | 0/75 |
| CholecystitisHepatobiliary disorders | 0/77 | 1/76 | 0/76 | 0/76 | 0/75 |
| COVID-19Infections and infestations | 0/77 | 1/76 | 0/76 | 0/76 | 0/75 |
| Multiple injuriesInjury, poisoning and procedural complications | 0/77 | 0/76 | 0/76 | 1/76 | 0/75 |
| Road traffic accidentInjury, poisoning and procedural complications | 0/77 | 0/76 | 1/76 | 0/76 | 0/75 |
| Diffuse large B-cell lymphomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/77 | 0/76 | 0/76 | 1/76 | 0/75 |
| Post-traumatic stress disorderPsychiatric disorders | 0/77 | 0/76 | 0/76 | 1/76 | 0/75 |
| Respiratory distressRespiratory, thoracic and mediastinal disorders | 0/77 | 0/76 | 1/76 | 0/76 | 0/75 |
| Deep vein thrombosisVascular disorders | 0/77 | 1/76 | 0/76 | 0/76 | 0/75 |
| Non-cardiac chest painGeneral disorders | 1/77 | 0/76 | 0/76 | 0/76 | 0/75 |
| Event | MK-0616 6 mg | MK-0616 12 mg | MK-0616 18 mg | MK-0616 30 mg | Placebo |
|---|---|---|---|---|---|
| COVID-19Infections and infestations | 6/77 | 1/76 | 5/76 | 4/76 | 7/75 |
| FatigueGeneral disorders | 0/77 | 3/76 | 1/76 | 0/76 | 5/75 |
| DyspepsiaGastrointestinal disorders | 1/77 | 5/76 | 3/76 | 0/76 | 1/75 |
| DiarrhoeaGastrointestinal disorders | 5/77 | 1/76 | 3/76 | 1/76 | 1/75 |
| NauseaGastrointestinal disorders | 1/77 | 1/76 | 4/76 | 2/76 | 0/75 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/77 | 4/76 | 1/76 | 2/76 | 1/75 |
| Age, Continuous(Years) | MK-0616 6 mg | MK-0616 12 mg | MK-0616 18 mg | MK-0616 30 mg | Placebo | Total |
|---|---|---|---|---|---|---|
| Mean | 61.7 ± 10.3 | 62.0 ± 9.4 | 62.0 ± 9.2 | 60.9 ± 10.2 | 60.6 ± 9.3 | 61.5 ± 9.7 |
| Sex: Female, Male(Participants) | MK-0616 6 mg | MK-0616 12 mg | MK-0616 18 mg | MK-0616 30 mg | Placebo | Total |
|---|---|---|---|---|---|---|
| Female | 38 | 35 | 39 | 38 | 38 | 188 |
| Male | 39 | 41 | 37 | 38 | 38 | 193 |
| Ethnicity (NIH/OMB)(Participants) | MK-0616 6 mg | MK-0616 12 mg | MK-0616 18 mg | MK-0616 30 mg | Placebo | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 26 | 29 | 31 | 31 | 37 | 154 |
| Not Hispanic or Latino | 51 | 46 | 45 | 45 | 38 | 225 |
| Unknown or Not Reported | 0 | 1 | 0 | 0 | 1 | 2 |
| Race (NIH/OMB)(Participants) | MK-0616 6 mg | MK-0616 12 mg | MK-0616 18 mg | MK-0616 30 mg | Placebo | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 4 | 5 | 5 | 2 | 5 | 21 |
| Asian | 18 | 13 | 11 | 13 | 8 | 63 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 4 | 5 | 2 | 9 | 4 | 24 |
| White | 49 | 48 | 55 | 44 | 54 | 250 |
| More than one race | 2 | 5 | 3 | 8 | 5 | 23 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Randomization Strata: Background Statin Dose(Participants) | MK-0616 6 mg | MK-0616 12 mg | MK-0616 18 mg | MK-0616 30 mg | Placebo | Total |
|---|---|---|---|---|---|---|
| No Statin Therapy | 30 | 29 | 31 | 30 | 30 | 150 |
| Low- to Moderate-intensity Statin Therapy | 27 | 27 | 26 | 26 | 26 | 132 |
| High-intensity Statin Therapy | 20 | 20 | 19 | 20 | 20 | 99 |
| Randomization Strata: Renal Function(Participants) | MK-0616 6 mg | MK-0616 12 mg | MK-0616 18 mg | MK-0616 30 mg | Placebo | Total |
|---|---|---|---|---|---|---|
| eGFR ≥60 ml/min/1.73 m^2 | 71 | 72 | 72 | 71 | 71 | 357 |
| eGFR <60 ml/min/1.73 m^2 | 6 | 4 | 4 | 5 | 5 | 24 |
| Baseline Low-density Lipoprotein Cholesterol (LDL-C)(mg/dL) | MK-0616 6 mg | MK-0616 12 mg | MK-0616 18 mg | MK-0616 30 mg | Placebo | Total |
|---|---|---|---|---|---|---|
| Mean | 116.5 ± 37.0 | 117.3 ± 36.4 | 123.7 ± 35.1 | 119.4 ± 36.7 | 120.7 ± 28.3 | 119.5 ± 34.8 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Mar 2022 to primary completion in Nov 2022, 8 months.
Results were first posted in Dec 2023, 1 year after primary completion.
Of 41 industry-sponsored phase 2 interventional studies under Hypercholesterolemia, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 14. This study's 8 months is below that.
Counting every sponsor, half of 48 studies reached it within 10 months; a quarter within 7 and three quarters within 18.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: MK-0616